NKTX

Company Overview — What Does Nkarta, Inc. Do?

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Nkarta, Inc. (NKTX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paul J. Hastings and employs approximately 140 people. With a market capitalization of $156M, NKTX is one of the notable companies in the Healthcare sector.

Nkarta, Inc. (NKTX) Stock Rating — Reduce (April 2026)

As of April 2026, Nkarta, Inc. receives a Reduce rating with a composite score of 35.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NKTX ranks #2,264 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nkarta, Inc. ranks #265 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NKTX Stock Price and 52-Week Range

Nkarta, Inc. (NKTX) currently trades at $2.21. The stock lost $0.13 (5.6%) in the most recent trading session. The 52-week high for NKTX is $2.81, which means the stock is currently trading -21.4% from its annual peak. The 52-week low is $1.31, putting the stock 68.7% above its annual trough. Recent trading volume was 795K shares, suggesting relatively thin trading activity.

Is NKTX Overvalued or Undervalued? — Valuation Analysis

Nkarta, Inc. (NKTX) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.51x, versus the sector average of 2.75x.

At current multiples, Nkarta, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nkarta, Inc. Profitability — ROE, Margins, and Quality Score

Nkarta, Inc. (NKTX) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -33.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -26.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NKTX Debt, Balance Sheet, and Financial Health

Nkarta, Inc. has a debt-to-equity ratio of 29.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.69x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $60M.

NKTX has a beta of 1.21, meaning it is more volatile than the broader market — a $10,000 investment in NKTX would be expected to move 20.6% more than the S&P 500 on any given day. The stability factor score for Nkarta, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nkarta, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nkarta, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.41. Net income for the quarter was $-105M. Operating income came in at $-125M.

In FY 2025, Nkarta, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.41. Net income for the quarter was $-104M. Operating income came in at $-122M.

In Q3 2025, Nkarta, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-22M. Operating income came in at $-27M.

In Q2 2025, Nkarta, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-23M. Operating income came in at $-27M.

Over the past 8 quarters, Nkarta, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing NKTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NKTX Dividend Yield and Income Analysis

Nkarta, Inc. (NKTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NKTX Momentum and Technical Analysis Profile

Nkarta, Inc. (NKTX) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

NKTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nkarta, Inc. (NKTX) ranks #265 out of 838 stocks based on the Blank Capital composite score. This places NKTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NKTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NKTX vs S&P 500 (SPY) comparison to assess how Nkarta, Inc. stacks up against the broader market across all factor dimensions.

NKTX Next Earnings Date

No upcoming earnings date has been announced for Nkarta, Inc. (NKTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NKTX? — Investment Thesis Summary

The quantitative profile for Nkarta, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Nkarta, Inc. (NKTX) earns a Reduce rating with a composite score of 35.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NKTX stock.

Related Resources for NKTX Investors

Explore more research and tools: NKTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NKTX head-to-head with peers: NKTX vs AZN, NKTX vs SLGL, NKTX vs VMD.